1. Presented By John Bartlett at 2017 ASCO Annual Meeting
Targeted sequencing in a phase III trial of luminal breast cancer: Identification of novel targets<br />
Presented By John Bartlett at 2017 ASCO Annual Meeting

2. TCGA/ICGC putting mutations in context
Presented By John Bartlett at 2017 ASCO Annual Meeting

3. Presented By John Bartlett at 2017 ASCO Annual Meeting
Use existing Phase III trial of current SOC to develop stratified medicine approaches to breast cancer
Presented By John Bartlett at 2017 ASCO Annual Meeting

4. Presented By John Bartlett at 2017 ASCO Annual Meeting
Gene panel selection:
Presented By John Bartlett at 2017 ASCO Annual Meeting

5. Pathway mapping for selected genes
Presented By John Bartlett at 2017 ASCO Annual Meeting

6. Presented By John Bartlett at 2017 ASCO Annual Meeting
Targeted sequencing
Presented By John Bartlett at 2017 ASCO Annual Meeting

7. ISOWN- a reference free somatic mutation caller
Presented By John Bartlett at 2017 ASCO Annual Meeting

8. Statistical analysis plan
Presented By John Bartlett at 2017 ASCO Annual Meeting

9. Mutational frequency in TEAM
Presented By John Bartlett at 2017 ASCO Annual Meeting

10. Gene associations with clinical features
Presented By John Bartlett at 2017 ASCO Annual Meeting

11. Impact of mutations in signaling modules
Presented By John Bartlett at 2017 ASCO Annual Meeting

12. Survival modelling using signalling cassettes
Presented By John Bartlett at 2017 ASCO Annual Meeting

13. Machine learning signature development
Presented By John Bartlett at 2017 ASCO Annual Meeting

14. Presented By John Bartlett at 2017 ASCO Annual Meeting
Model 45
Presented By John Bartlett at 2017 ASCO Annual Meeting

15. Presented By John Bartlett at 2017 ASCO Annual Meeting
Conclusions:
Presented By John Bartlett at 2017 ASCO Annual Meeting

16. Limitations/Future directions
Presented By John Bartlett at 2017 ASCO Annual Meeting

17. Presented By John Bartlett at 2017 ASCO Annual Meeting
Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. Abstract (Bayani J et al.,)<br /><br />
Presented By John Bartlett at 2017 ASCO Annual Meeting

18. Presented By John Bartlett at 2017 ASCO Annual Meeting
Acknowledgements
Presented By John Bartlett at 2017 ASCO Annual Meeting